Pharmaceuticals

Why revenue hunters ought to go for dividend compounders over high-yielding shares

What to consider ‘Peak 65’

J&J, Merck and Bristol Myers CEOs, below fireplace on Capitol Hill, search to show up warmth on drug-market middlemen 

This fund supervisor stopped worrying about economics. Now he’s outperforming the inventory market.

Amgen’s quarterly outcomes prime expectations regardless of Enbrel gross sales decline

Novartis to bolster its oncology portfolio with acquisition of MorphoSys

Small companies are paying 100%+ of earnings to Uncle Sam after tax-law change

Elanco’s inventory heads for 18-month excessive as firm sells aqua enterprise to Merck for $1.3 billion in money

Novo Nordisk’s controlling shareholder to purchase Catalent for $16.5 billion

Some board members felt pressured to take medication with Elon Musk, WSJ experiences